全文获取类型
收费全文 | 128222篇 |
免费 | 13315篇 |
国内免费 | 8494篇 |
专业分类
耳鼻咽喉 | 1085篇 |
儿科学 | 2188篇 |
妇产科学 | 1532篇 |
基础医学 | 12355篇 |
口腔科学 | 2294篇 |
临床医学 | 17796篇 |
内科学 | 15868篇 |
皮肤病学 | 1373篇 |
神经病学 | 5286篇 |
特种医学 | 4299篇 |
外国民族医学 | 36篇 |
外科学 | 10135篇 |
综合类 | 26734篇 |
现状与发展 | 36篇 |
一般理论 | 10篇 |
预防医学 | 11800篇 |
眼科学 | 3200篇 |
药学 | 14877篇 |
183篇 | |
中国医学 | 10029篇 |
肿瘤学 | 8915篇 |
出版年
2024年 | 531篇 |
2023年 | 1949篇 |
2022年 | 4995篇 |
2021年 | 6307篇 |
2020年 | 5080篇 |
2019年 | 3914篇 |
2018年 | 4065篇 |
2017年 | 4264篇 |
2016年 | 3791篇 |
2015年 | 5768篇 |
2014年 | 7319篇 |
2013年 | 7493篇 |
2012年 | 10672篇 |
2011年 | 11374篇 |
2010年 | 8252篇 |
2009年 | 6969篇 |
2008年 | 8016篇 |
2007年 | 7847篇 |
2006年 | 7242篇 |
2005年 | 6144篇 |
2004年 | 4559篇 |
2003年 | 4332篇 |
2002年 | 3630篇 |
2001年 | 2919篇 |
2000年 | 2416篇 |
1999年 | 2119篇 |
1998年 | 1278篇 |
1997年 | 1206篇 |
1996年 | 964篇 |
1995年 | 840篇 |
1994年 | 778篇 |
1993年 | 417篇 |
1992年 | 454篇 |
1991年 | 392篇 |
1990年 | 366篇 |
1989年 | 296篇 |
1988年 | 280篇 |
1987年 | 227篇 |
1986年 | 185篇 |
1985年 | 122篇 |
1984年 | 94篇 |
1983年 | 38篇 |
1982年 | 27篇 |
1981年 | 29篇 |
1980年 | 19篇 |
1979年 | 10篇 |
1977年 | 6篇 |
1972年 | 6篇 |
1971年 | 6篇 |
1969年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
21.
Gui-Qi Zhu Ke-Qing Shi Sha Huang Gui-Qian Huang Yi-Qian Lin Zhi-Rui Zhou Martin Braddock Yong-Ping Chen Ming-Hua Zheng 《Medicine》2015,94(11)
Major ursodeoxycholic acid (UDCA)-based therapies for primary biliary cirrhosis (PBC) include UDCA only, or combined with either methotrexate (MTX), corticosteroids (COT), colchicine (COC), or bezafibrate (BEF). As the optimum treatment regimen is unclear and warrants exploration, we aimed to compare these therapies in terms of patient mortality or liver transplantation (MOLT) and adverse events (AE).PubMed, the Cochrane Library, and Scopus were searched for randomized controlled trials up to August 31, 2014. We estimated the hazard ratios (HRs) for MOLT and odds ratios (ORs) for AE. A sensitivity analysis based on the dose of UDCA was also executed.Thirty-one eligible articles were included. Compared with COT plus UDCA, UDCA (HR 0.38, 95% confidence interval [CI] 0.09–1.39), BEF plus UDCA (HR 0.29, 95% CI 0.02–4.83), COC plus UDCA (HR 0.39, 95% CI 0.07–2.25), MTX plus UDCA (HR 0.28, 95% CI 0.05–1.63), or OBS (HR 0.49, 95% CI 0.11–2.01) all provided an increased risk of MOLT. With respect to drug AE profile, although not differing appreciably, BEF plus UDCA was associated with more AEs compared with UDCA (OR 3.16, 95% CI 0.59–20.67), COT plus UDCA (OR 2.27, 95% CI 0.15–33.36), COC plus UDCA (OR 1.00, 95% CI 0.09–12.16), MTX plus UDCA (OR 2.03, 95% CI 0.23–17.82), or OBS (OR 3.00, 95% CI 0.53–20.75). The results of sensitivity analyses were highly consistent with previous analyses.COT plus UDCA was the optimal UDCA-based regimen for both MOLT and AEs. BEF plus UDCA was most likely to cause AEs, whereas monotherapy with UDCA and coadministriation of COT plus UDCA appeared to be associated with the fewest AEs for PBC treatment. 相似文献
22.
Xiujuan Tian Zhiying Chen Shaomin Shi Xianwen Wang Wanli Wang Ning Li Jing Wang 《Medicine》2015,94(37)
Oral cancer, predominantly oral squamous cell carcinoma (OSCC), is one of the most leading causes of cancers worldwide. Due to a low 5-year survival rate, highly effective methods for the early detection of OSCC are totally needed. MicroRNAs (miRNAs), as promising biomarkers, can bring insights into tumorigenesis of oral cancers. However, studies on the accuracy of miRNAs detection in OSCC have inconsistent conclusions, leading us to conduct this meta-analysis. The aim of this study was to systematically review the articles investigating the diagnostic value of miRNAs in OSCC.The PubMed, Embase, Chinese National Knowledge Infrastructure (CNKI), Web of Science were searched (updated to June 11th, 2015) to identify all articles evaluating the diagnostic yield of miRNAs for OSCC. The pooled sensitivity, specificity, and other diagnostic parameters were used to assess the performance of miRNAs assays on OSCC detection. Statistical analysis was conducted by employing the R software.The present meta-analysis comprised 23 studies from 10 articles, including 598 OSCC patients and 320 healthy individuals, available for analysis. The summary receiver operator characteristic (SROC) curve was plotted. Meanwhile, the pooled diagnostic parameters and the area under curve (AUC) were calculated based on all included studies. The pooled diagnostic parameters calculated from all 23 studies were as follows: pooled sensitivity of 0.759 (95% CI: 0.701–0.809), pooled specificity of 0.773 (95% CI: 0.713–0.823) and AUC of 0.832, which indicates a relatively high diagnostic accuracy of miRNAs in differentiating OSCC patients from healthy controls. Meanwhile, In addition, subgroup analyses were conducted to access the heterogeneity between studies, which is based on specimen (serum/plasma/blood/saliva/ tissue) and ethnicity (Asian/Caucasian).In summary, our meta-analysis suggests that miRNAs might be used in noninvasive screening tests for OSCC, which needs further large-scale studies to be validated. 相似文献
23.
目的分析成人血液系统恶性肿瘤患者接受强烈化疗后中性粒细胞减少性肠炎(NE)的发生率、危险因素及预后情况。方法收集2004至2013年接受化疗的1804例血液系统恶性肿瘤患者,记录患者血常规、凝血检测和血液生化检测结果,并记录患者年龄、性别、原发病、既往化疗次数、既往化疗方案中是否使用阿糖胞苷、临床症状、肠壁厚度、中性粒细胞最低计数、中性粒细胞缺乏持续时间、NE的治疗方法和预后等,探讨NE起病诱因、临床特征、腹部B超特点、症状的预后意义及化疗药物对发病的影响等。结果1804例患者中226例(12.5%)化疗后合并NE,化疗后10~19d起病,中位起病时间为化疗后第14天。发生NE后26例患者死亡,病死率11.5%。化疗药物包括阿糖胞苷、临床症状≥4项、中性粒细胞缺乏持续超过7d以及B超下肠壁厚度≥10mm的患者病死率相对较高。结论NE是接受强烈化疗的血液系统肿瘤患者的严重的并发症,发生NE后患者病死率较高。 相似文献
24.
25.
目的 采用Meta分析对比四维子宫输卵管超声造影(4D-HyCoSy)与子宫输卵管造影(HSG)评估输卵管通畅性的效能。方法 系统搜索PubMed、Cochrane Library、Embase、Web of Science、中国生物医学文献数据库、中国知网、万方医学网及维普数据库中建库至今有关4D-HyCoSy和/或HSG评估输卵管通畅性的文献。由2名研究人员依据纳入标准和排除标准筛选文献并提取信息;分别计算4D-HyCoSy和HSG评估输卵管通畅性的合并敏感度(SEN)、特异度(SPE)及诊断比值比(DOR),绘制综合受试者工作特征(SROC)曲线,获得曲线下面积(AUC),并以Medcalc 19.1.1统计软件比较AUC。结果 最终纳入19篇文献、1 358例疑似输卵管因素导致不孕患者,其中4篇同时采用4D-HyCoSy及HSG评估输卵管通畅性,10篇仅以4D-HyCoSy评估,5篇仅以HSG评估。Meta分析结果显示,4D-HyCoSy评估输卵管通畅性的合并SEN、SPE及DOR分别为0.92[95%CI(0.91,0.94)]、0.91[95%CI(0.89,0.93)]及115.06[95%CI(54.23,224.10)];HSG评估输卵管通畅性的合并SEN、SPE及DOR分别为0.84[95%CI(0.81,0.87)]、0.80[95%CI(0.76,0.83)]及28.64[95%CI(10.08,81.35)]。4D-HyCoSy评估输卵管通畅性的AUC为0.98[95%CI(0.96,0.99)],HSG为0.93[95%CI(0.90,0.95)],差异有统计学意义(Z=6.97,P<0.01)。结论 4D-HyCoSy评估输卵管通畅性的效能高于HSG。 相似文献
26.
27.
28.
29.
30.